News
LUMO
--
0.00%
--
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021 and w...
GlobeNewswire · 05/19 13:00
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 05/14 19:30
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hostin...
GlobeNewswire · 05/13 13:38
10-Q: LUMOS PHARMA, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 05/06 19:16
Lumos Pharma EPS misses by $0.17
Lumos Pharma (LUMO): Q1 GAAP EPS of -$1.04 misses by $0.17.Cash and cash equivalents of $114.1MPress Release
Seekingalpha · 05/05 20:22
Lumos Pharma Q1 EPS $(1.04) Misses $(0.87) Estimate
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.87) by 19.54 percent. This is a 642.86 percent decrease over losses of $(0.14) per share from
Benzinga · 05/05 20:11
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely...
GlobeNewswire · 05/05 20:01
Lumos Pharma Inc to Host Earnings Call
May 05, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Lumos Pharma Inc (NASDAQ:LUMO) will be discussing their earnings results in...
ACCESSWIRE · 05/05 18:30
Earnings Scheduled For May 5, 2021
  Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
Benzinga · 05/05 08:15
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.
Benzinga · 05/01 17:19
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
AUSTIN, Texas, Apr 28, 2021 (GLOBE NEWSWIRE via COMTEX) -- AUSTIN, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a...
GlobeNewswire · 04/28 13:00
JonesTrading Thinks Lumos Pharma’s Stock is Going to Recover
In a report released today, Lina Kaminski from JonesTrading reiterated a Buy rating on Lumos Pharma (LUMO), with a price target of $34.00. The company's
SmarterAnalyst · 04/27 21:25
BRIEF-Lumos Pharma To Present New Data On Three PGHD Patients Treated With Lum-201 In Prior Phase 2 Study
reuters.com · 04/27 12:21
Lumos Pharma Says Newly Released Data On 3 PGHD Patients Treated With LUM-201 In Prior Phase 2 Study To Be Presented In Lumos Pharma Key Option Leader Webinar
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that new data highlights from three patients with pediatric growth hormone
Benzinga · 04/27 12:02
Lumos Pharma CFO retires, picks internal candidate for succession
Lumos Pharma (LUMO) CFO Carl Langren has announced his plans to retire effective as of July 4, 2021; Mr. Langren has served as CFO of the Company since November 2018.He will continue to
Seekingalpha · 04/20 20:14
Lumos Pharma Chief Financial Officer to Retire in July; Successor Named
MT Newswires · 04/20 17:00
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ETAUSTIN, Texas, April 14, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today t...
GlobeNewswire · 04/14 21:05
Analysts Are Bullish on These Healthcare Stocks: Lumos Pharma (LUMO), Crinetics Pharmaceuticals (CRNX)
SmarterAnalyst · 03/23 10:15
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagoguesAUSTIN, Texas, March 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused o...
GlobeNewswire · 03/20 15:00
Webull provides a variety of real-time LUMO stock news. You can receive the latest news about Lumos Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LUMO
Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.